under investigation and with the diseases for which screening is being conducted. More work is needed on the evaluation of screening programmes conducted on people who already have symptoms and signs of disease, i.e. on patients, and much more learned about the natural history of diseases and their development before screening programmes on well populations should be greatly expanded. Also, for the application of screening to well populations to be successful, advances in treatment must be made.
Dr LI Wooflf (Radcliffe Infirmary, Oxford)
P2diatric Screening for Genetically Determined Metabolic Diseases
The theory that the clinical effects in phenylketonuria were the result of intoxication by phenylalanine starting soon after birth led to the therapeutic use of a diet low in phenylalanine. This, to a large extent, prevented mental and neurological deterioration if treatment was started in very early infancy, before any clinical " chromatography of blood amino-acids (Scriver et al. 1964 , Efron et al. 1964 ), spectrophotofluorometric assay of phenylalanine in blood (Hill et al. 1965 , Searle et aL. 1967 ) and chromatography of urine for o-hydroxyphenylacetic acid (Woolf 1967b) . Each test has its advantages and disadvantages but all make small demands on skilled manpower in the laboratory or the field, use inexpensive materials and easily collected specimens, are reliable and raise few administrative problems.
There are a number of other treatable genetically determined metabolic diseases. It is desirable to detect as many as possible with a single test or, second best, to use the same specimen for different tests. The two chromatographic techniques score heavily in this and the bacterial inhibition assay promnises to 'be adaptable as a 'multiple screen' in the near future.
